|
GENE
|
polymorphism
|
N° of acute rejection episodes
|
|---|
|
CYP3A5
|
AG (n = 12) (24.4%)
|
5* (41.6%)
|
|
GG (n = 37) (75.5%)
|
3 (1.0%)
|
|
CYP3A4B
|
AA (n = 43) (87.7%)
|
7 (16.2%)
|
|
AG (n = 6) (12.2%)
|
1 (16.6%)
|
|
SXR A7635G
|
AA (n = 16) (32.6%)
|
2 (12.5%)
|
|
AG (n = 24) (48.9%)
|
6 (25.0%)
|
|
GG (n = 9) (18.3%)
|
0* (0.0%)
|
|
SXR RS rs3842689
|
In/in (n = 19) (38.7%)
|
3 (12.9%)
|
|
In/del (n = 22) (44.8%)
|
4 (18.1%)
|
|
Del/del (n = 8) (16.32%)
|
1 (12.5%)
|
|
ABCB1 C1236T
|
CC (n = 18) (36.7%)
|
3 (16.6%)
|
|
CT (n = 19) (38.7%)
|
2 (10.5%)
|
|
TT (n = 12) (24.4%)
|
3 (0.25%)
|
|
ABCB1 G2677T/A
|
GG (n = 16) (32.6%)
|
2 (12.5%)
|
|
GT/A (n = 26) (53.0%)
|
5 (19.2%)
|
|
TT (n = 7) (14.2%)
|
1 (14.2%)
|
|
ABCB1 C3435T
|
CC (n = 15) (30.6%)
|
4 (26.6%)
|
|
CT (n = 24) (48.9%)
|
2 (8.3%)
|
|
TT (n = 10) (20.4%)
|
2 (20.0%)
|
- * p-value < 0.05 at Fisher exact test
